Anatara Lifesciences Ltd Asset Resilience Ratio
Anatara Lifesciences Ltd asset resilience ratio. Anatara Lifesciences Ltd (ANR) has an Asset Resilience Ratio of 2.84% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anatara Lifesciences Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Anatara Lifesciences Ltd (2015–2024)
Asset resilience ratio of Anatara Lifesciences Ltd from 2015 to 2024. This chart shows how Anatara Lifesciences Ltd's Asset Resilience Ratio has changed over time. Read ANR total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Anatara Lifesciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Anatara Lifesciences Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$50.00K | 2.84% |
| Total Liquid Assets | AU$50.00K | 2.84% |
Asset Resilience Insights
- Limited Liquidity: Anatara Lifesciences Ltd maintains only 2.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anatara Lifesciences Ltd Industry Peers by Asset Resilience Ratio
Compare Anatara Lifesciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Anatara Lifesciences Ltd Asset Resilience Ratio by Year (2015–2024)
Anatara Lifesciences Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Anatara Lifesciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 3.00% | AU$50.09K ≈ $35.44K |
AU$1.67 Million ≈ $1.18 Million |
-0.53pp |
| 2023-06-30 | 3.52% | AU$50.00K ≈ $35.38K |
AU$1.42 Million ≈ $1.00 Million |
+0.69pp |
| 2022-06-30 | 2.83% | AU$50.00K ≈ $35.38K |
AU$1.77 Million ≈ $1.25 Million |
+1.67pp |
| 2021-06-30 | 1.16% | AU$50.00K ≈ $35.38K |
AU$4.33 Million ≈ $3.06 Million |
-- |
| 2020-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$3.34 Million ≈ $2.37 Million |
-- |
| 2019-06-30 | 63.46% | AU$4.05 Million ≈ $2.87 Million |
AU$6.38 Million ≈ $4.52 Million |
+0.27pp |
| 2018-06-30 | 63.19% | AU$6.20 Million ≈ $4.39 Million |
AU$9.81 Million ≈ $6.94 Million |
-24.99pp |
| 2017-06-30 | 88.17% | AU$10.86 Million ≈ $7.68 Million |
AU$12.32 Million ≈ $8.71 Million |
+34.74pp |
| 2016-06-30 | 53.43% | AU$7.44 Million ≈ $5.26 Million |
AU$13.92 Million ≈ $9.85 Million |
-18.59pp |
| 2015-06-30 | 72.03% | AU$4.05 Million ≈ $2.87 Million |
AU$5.63 Million ≈ $3.98 Million |
-- |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more